De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?
Fabien Moinard-Butot, Simon Nannini, Gwénaëlle Gravis, Marie Pautas et autres
0 citationsClinical Genitourinary Cancer
Gwénaëlle Gravis
Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.
726Publications signalées
24601Citations signalées
6Affiliations récentes
Institutions déclarées
Domaines associés
Prostate Cancer Treatment and ResearchRenal cell carcinoma treatmentBladder and Urothelial Cancer TreatmentsCancer Immunotherapy and BiomarkersProstate Cancer Diagnosis and Treatment
Publications récentes
Papillary renal cell carcinoma – exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review
Marit Ahrens, John Haanen, Laurence Albigès, Marine Gross‐Goupil et autres
1 citationEuropean Journal of Cancer
Neoadjuvant Durvalumab ± Tremelimumab in Combination With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Muscle-Invasive Bladder Carcinoma: Results of the Phase I/II NEMIO Study
Constance Thibault, Mostefa Bennamoun, Aude Fléchon, Gwénaëlle Gravis et autres
0 citationsJournal of Clinical Oncology
Chemotherapy-induced anemia as a prognostic factor for overall survival in patients with bladder cancer treated with neoadjuvant cisplatin-based chemotherapy and cystectomy
Elsa Lafitte, Patrick Sfumato, J. Walz, Emilien Billon et autres
0 citationsWorld Journal of Urology
A phase 1/2, open-label, randomized, dose-finding and dose expansion study of gedatolisib in combination with darolutamide in metastatic castration-resistant prostate cancer (mCRPC).
Adam Sharp, J. de Bono, Frank C. Cackowski, Begoña Mellado et autres
0 citationsJournal of Clinical Oncology
A randomised, multicentre, phase II trial of active surveillance with or without six months of apalutamide for prostate cancer.
Gwénaëlle Gravis, Patrick Sfumato, G. Ploussard, P.-H. Savoie et autres
0 citationsJournal of Clinical Oncology
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study
B. Blanchet, Alicja Puszkiel, Anne Jouinot, M. Bennamoun et autres
1 citationBritish Journal of Cancer
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum
Denis Lacombe, Fábio Cardoso Borges, Ana E. Amariutei, Christopher M. Booth et autres
1 citationJournal of Cancer Policy
Hyperprogression after Immune Checkpoint Inhibitors: A Cloudy Phenomenon with Real-life Consequences
Damien Bruyat, Nicolas Girard, Pierre Heudel, Nicolas Penel et autres
0 citations癌症：英文版
Fumarate hydratase-deficient renal cell carcinoma – results of the exploratory analysis in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line treatment
Marit Ahrens, John Haanen, Laurence Albiges, Marine Gross‐Goupil et autres
0 citationsCancer Treatment and Research Communications
Local and locoregional prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Jochen Walz, G. Attard, Anders Bjartell, Pierre Blanchard et autres
12 citationsAnnals of Oncology
Nivolumab in Metastatic Clear-cell Renal Cell Carcinoma: An Integrative Biomarker Analysis from the NIVOREN GETUG-AFU 26 Phase 2 Study
Ronan Flippot, Yann Vano, Cécile Dalban, Benoit Beuselinck et autres
1 citationEuropean Urology
BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, ROR et la Banque mondiale, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune donnée externe enregistrée en base. Sources et limites.